Dr. Steve Reed is Curevo Vaccine’s Scientific Advisory and Executive Board Member. Dr. Reed is the founding CEO of start-up ONC Bio. He joined the Seattle Biomedical Research Institute in 1984 until founding Infectious Disease Research Institute in 1993. He has received over $100 million in grants from the US NIH, BARDA, DARPA, and the Gates Foundation. In 1994 he co-founded Corixa Corporation (which was later sold to GlaxoSmithKline, GSK) where he served as Chief Scientific Officer until 2004. He also founded Dharma Therapeutics, a transdermal patch company, where he served as President from 2005-2008. In 2008 Dr. Reed, co-founded Immune Design Corp., a cancer therapeutics company, where he served as CEO until 2011 (Immune Design was recently acquired by Merck). Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of vaccines and diagnostics for both cancer and infectious diseases. In partnership with GSK, he led the team that developed the first defined tuberculosis vaccine, now in advanced clinical development. He also developed the first defined vaccines for leishmaniasis, as well as the K39-based diagnostic tests currently licensed for leishmaniasis. He has more than 400 original publications, 35 book chapters and reviews, and 105 issued patents on diagnostics, vaccines, and therapeutics of adjuvants, cancer, and infectious diseases.